Top1031

Kindeva Drug Delivery Global Headquarters

Life sciences industrial property in Woodbury, MN · sponsored by NexPoint

Active offeringLatest Form D filed Aug 11, 2026 · 17 filings since Jan 31, 2024 (opens in a new tab)

Kindeva Drug Delivery Global Headquarters is a DST sponsored by NexPoint that owns a life sciences industrial property in Woodbury, MN. Its latest Form D, filed Aug 11, 2026, lists a $30.6 million offering with a $100,000 minimum.

Key facts

Minimum investment
$100,000
From the Form D
Offering size
$30,661,253
Equity offered, per the Form D
Sold so far
91.2%
Form D, Aug 11, 2026; the % is our arithmetic
Investors reported
92
Form D, Aug 11, 2026
Selling commissions
$2,682,859 · 8.7% of offering
Form D Item 15; the % is our arithmetic
Financing
Leveraged. This offering reports mortgage debt on the property.
How it is financed ↓
Offered under
Rule 506(c)
May be advertised publicly. Every buyer’s accredited status must be verified.

Figures come from SEC Form D filings unless a source is cited. Sponsor-stated figures are as reported by the sponsor; Top1031 does not independently audit them. On a 45-day clock? Find day 45 and day 180 →

Sales so far

Latest Form D
Aug 11, 2026 · 17 filings
First sale
Jan 25, 2024

These are the sponsor’s own numbers. They can lag what has actually sold, and they do not confirm that interests are still available.

How we work out how much has sold

We divide the amount the sponsor reports sold by the offering size in its latest SEC filing, filed Aug 11, 2026.

  • The sponsor reports these amounts itself, and can amend them later.
  • A filing can be behind what has actually sold. It does not confirm that interests are still available.
  • The amount left to sell is the offering size minus the amount sold.
Amount sold
$27,965,695
Not yet sold
$2,695,558
Investors
92

Calculated by Top1031 from the Form D filings, not stated by the sponsor:

91.2% of $30,661,253 sold, calculated by Top1031 from the Form D

Average since first sale
about $916,260 a month
See how much of this offering has soldSign in by email and confirm you’re an accredited investor.

Weighing this offering for your exchange? A licensed 1031 specialist from our affiliated partner can go through these filings with you.

Ask a 1031 specialist about this recordFree. About: Kindeva Drug Delivery Global Headquarters. Top1031 is not a broker-dealer.
Kindeva Drug Delivery Global Headquarters image 1 of 3

Kindeva Drug Delivery Global Headquarters · Woodbury, MN · Photo: nexpoint.com

Location map11200 Hudson Road, Woodbury, MNAddress matched to a cited source

What does the Trust own?

The building is a built-to-suit life sciences property in the eastern Twin Cities metro, pairing offices with research and cGMP manufacturing space, the controlled conditions regulators require for making drug products. 1 NexPoint announced the trust on January 16, 2024, describing a contract-manufacturing property in Minnesota; a footnote to that announcement said the purchase had not yet closed. 2

Property address
11200 Hudson Road, Woodbury, MN
Property size
137,811 SF on 11.7 acres (43,565 SF R&D/cGMP space, 2 floors + mezzanine, 250 parking spaces, built 2021)
Total funding
$61,961,253
Investor money plus any loan.
Property acquisition cost
$59,094,426
Who can invest
Accredited investors only
Tenant
Kindeva Drug Delivery L.P. (triple net lease, built-to-suit global HQ)

How have sales gone?

The sponsor’s own numbers, with the caveat in Sales so far ↑.

Share of the offering sold at each Form D filing date, calculated by Top1031 from the filed amounts
0%50%100%0.4%91.2%Jan 31, 2024Aug 11, 20260%50%100%0.4%91.2%Jan 31, 2024Aug 11, 2026

How is it financed, and what did it cost to sell?

The Trust carries a mortgage, so investor equity sits behind debt that is repaid first, and an exchanger can use that debt to replace a loan on the property they sold. NexPoint's brochure states a loan of $31,300,000; its property webpage shows $30,661,253. 4

Debt

Financing
Leveraged. This offering reports mortgage debt on the property.
Interest rate
4.50% fixed
Loan term
9 years, interest-only through December 2025
Loan share of total funding
50.52%
The loan measured against investor money plus the loan.

Costs and terms from the Form D

Selling commissions
$2,682,859 · 8.7% of offering
Finders’ fees
$0
Paid to officers, directors and promoters
$761,468 · 2.4% of offering
Form D Item 16
· The filing’s note: “Item 16 is an estimate of offering expenses and acquisition fees that may accrue to one or more Related Persons.”
Broker-dealers named in the Form D
16 named in the Form D
Show the firms

Individual representatives named in Item 12 are not listed.

Date of first sale
Jan 25, 2024
Minimum investment
$100,000

Form D Item 15 and Item 16 amounts may be the issuer’s estimates; each percentage is Top1031’s arithmetic on two Form D figures. Item 16 can overlap Item 15, so Top1031 does not add them together. The issuer marked these amounts as an estimate.

What does the SEC record show?

Form D is the SEC notice an issuer files after its first private sale; the issuer gave January 25, 2024 as that first sale date. 6 Amendments have followed, each refreshing the tallies the form reports. Rule 506(c) allows public advertising but requires NexPoint to document each buyer's accredited status.

Legal Trust name
NexPoint Life Sciences III DST
SEC CIK
2008210
First Form D
Jan 31, 2024
Latest Form D
Aug 11, 2026
Filings on record
17
Offered under
Rule 506(c)
May be advertised publicly. Every buyer’s accredited status must be verified.
Source filing
Read the filings on SEC EDGAR

SEC Form D filings, newest first

FiledFormOffering amountAmount soldInvestors
Form D/A$30,661,253
$27,965,695+$2,786,906
92+11
EDGAR
Form D/A$30,661,253
$25,178,789+$11,028,000
81+22
EDGAR
Form D/A$30,661,253
$14,150,789+$2,613,776
59+12
EDGAR
Form D/A$30,661,253
$11,537,013+$1,671,367
47+6
EDGAR
Form D/A$30,661,253
$9,865,646+$300,000
41+1
EDGAR
Form D/A$30,661,253
$9,565,646+$955,107
40+3
EDGAR
Form D/A$30,661,253
$8,610,539+$2,043,773
37+6
EDGAR
Form D/A$30,661,253
$6,566,766+$1,776,929
31+7
EDGAR
Form D/A$30,661,253
$4,789,837+$591,084
24+3
EDGAR
Form D/A$30,661,253
$4,198,753+$175,000
21+2
EDGAR
Form D/A$30,661,253
$4,023,753+$1,110,622
19+5
EDGAR
Form D/A$30,661,253
$2,913,131+$966,273
14+4
EDGAR
Form D/A$30,661,253
$1,946,858+$395,000
10+3
EDGAR
Form D/A$30,661,253
$1,551,858+$1,034,452
7+3
EDGAR
Form D/A$30,661,253
$517,406+$100,000
4+1
EDGAR
Form D/A$30,661,253
$417,406+$268,877
3+2
EDGAR
Form D$30,661,253
$148,529
1
EDGAR
Show all 17 SEC Form D filings

Amounts, investor counts and minimums are as filed with the SEC on Form D. The change lines are Top1031’s arithmetic between consecutive filings; a new Form D notice starts a new count.

A Form D is the notice a sponsor files when it starts raising money. A Form D filing does not mean the SEC approved, endorsed, or verified the offering.

Common questions

Is Kindeva Drug Delivery Global Headquarters an active offering?
Kindeva Drug Delivery Global Headquarters is an Active offering: its latest Form D was filed Aug 11, 2026. A Form D filing does not by itself confirm that interests are still available; the sponsor or a registered representative can confirm what is open.
What does NexPoint Life Sciences III DST own?
A single life sciences and manufacturing building at 11200 Hudson Road in Woodbury, Minnesota, in the eastern Twin Cities metro. The property runs 137,811 square feet on 11.7 acres, was built in 2021, and includes 43,565 square feet of research and cGMP manufacturing space across two floors plus a mezzanine, with 250 parking spaces. NexPoint's offering page describes it as built to suit for its occupant.
Who is the tenant, and what does the lease say?
Kindeva Drug Delivery L.P., a contract development and manufacturing organization that occupies the building as its global headquarters. The lease is triple net, so the tenant pays property taxes, insurance and building upkeep. Baker 1031's offering summary reports the building 100% leased to Kindeva on a 15-year lease expiring September 30, 2036. With one building and one tenant, the rent depends on that single company; rent steps, renewal options and any guaranty are set out in the offering documents.
How is the Trust financed?
With a mortgage on the property, which makes this a leveraged offering. The recorded terms are a 4.50% fixed rate over a nine-year term, with interest-only payments through December 2025, and the loan equals 50.52% of total funding. NexPoint's offering brochure specifies a $31,300,000 loan amount, while its own property webpage displays $30,661,253.
What is the minimum investment, and who can buy in?
The minimum is $100,000, which may be funded with cash or with 1031 exchange proceeds. Interests are sold only to accredited investors, people who meet the SEC's income or net worth tests. Because the offering may be made under Rule 506(c), which permits general advertising, the sponsor verifies accredited status with documents such as tax returns or a third-party letter.
Is there a 721 or UPREIT exit?
No. A 721 or UPREIT exit is a structure in which a DST's property is later contributed to a REIT's operating partnership in exchange for units, turning a direct real estate interest into REIT-level securities. This Trust's record shows no such conversion path, so a sale or refinancing of the single property is the exit route the record points to.
Who sponsors the Trust?
NexPoint, which runs a 1031 exchange platform alongside a broader real estate business. The issuer's Form D names NexPoint Real Estate Advisors IV, L.P. as the sponsor and identifies the issuer as a Delaware statutory trust organized in 2023. NexPoint announced the offering on January 16, 2024, and trade outlet AltsWire reported the launch the following day.

In the news

Sources

Show sources (8)Hide sources (8)

These links support the record as a whole; individual details may come from different sources.

DST interests are illiquid private securities. You may lose some or all of your investment. Distributions, tax treatment, and exit timing are not guaranteed. Review the current offering documents before investing.